Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126397131 | 12639713 | 1 | I | 20100618 | 20100707 | 20160810 | 20160810 | EXP | US-ROCHE-715250 | ROCHE | 66.97 | YR | M | Y | 96.00000 | KG | 20160810 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126397131 | 12639713 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | 203388 | CAPSULE | ||||||||||
| 126397131 | 12639713 | 2 | SS | Vismodegib | VISMODEGIB | 1 | 203388 | ||||||||||||
| 126397131 | 12639713 | 3 | SS | Erlotinib | ERLOTINIB | 1 | Oral | 100MG, QD | 53728 | 100 | MG | TABLET | QD | ||||||
| 126397131 | 12639713 | 4 | SS | Erlotinib | ERLOTINIB | 1 | Oral | 75MG, QD | 53728 | 75 | MG | TABLET | QD | ||||||
| 126397131 | 12639713 | 5 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | FREQUENCY: DAYS 1, 8 AND 15 | U | 0 | 1000 | MG/M**2 | |||||||
| 126397131 | 12639713 | 6 | C | DILTIAZEM. | DILTIAZEM | 1 | 0 | ||||||||||||
| 126397131 | 12639713 | 7 | C | LOVASTATIN. | LOVASTATIN | 1 | 0 | ||||||||||||
| 126397131 | 12639713 | 8 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | 0 | ||||||||||||
| 126397131 | 12639713 | 9 | C | PROPAFENONE. | PROPAFENONE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126397131 | 12639713 | 1 | Pancreatic carcinoma |
| 126397131 | 12639713 | 2 | Adenocarcinoma pancreas |
| 126397131 | 12639713 | 3 | Pancreatic carcinoma |
| 126397131 | 12639713 | 4 | Adenocarcinoma pancreas |
| 126397131 | 12639713 | 5 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126397131 | 12639713 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126397131 | 12639713 | Decreased appetite | |
| 126397131 | 12639713 | Dehydration | |
| 126397131 | 12639713 | Diarrhoea | |
| 126397131 | 12639713 | Fatigue | |
| 126397131 | 12639713 | Hypokalaemia | |
| 126397131 | 12639713 | Hyponatraemia | |
| 126397131 | 12639713 | Lung infection | |
| 126397131 | 12639713 | Nausea | |
| 126397131 | 12639713 | Non-cardiac chest pain | |
| 126397131 | 12639713 | Pneumonia | |
| 126397131 | 12639713 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |